Samuel Denmeade, MD
Enriched profileR. Dale Hughes Professor of Oncology, Urology and Pharmacology and Molecular Sciences; Director of Genitourinary Oncology Division · Johns Hopkins University School of Medicine
Samuel Denmeade is R. Dale Hughes Professor of Oncology, Urology and Pharmacology and Molecular Sciences; Director of Genitourinary Oncology Division at Johns Hopkins University School of Medicine. OpenAlex indexes 546 publications with 17,589 citations (h-index 65); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 23 Oct 2026
Samuel Denmeade, M.D., is R. Dale Hughes Professor of Oncology, Urology and Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine. The public record shows 546 publications with 17,589 citations (h-index 65), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Vitamin C and Antioxidants Research. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 5 companies, 7 NIH-funded awards (2006–2026).
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Prostate Cancer Treatment and Research
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 179.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- The COSMYC Trial (COmbined Suppression of MYC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 23 Oct 2026
5 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20241 payment
- MACROGENICS, INC.Program year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.6%Cytochrome P450 17A1 Inhibitor38.8%Abiraterone Acetate100%Part D≥30 patientsAndrogen Receptor Inhibitor2.4%Xtandi100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
37.2%Corticosteroid37.2%Prednisone100%Part D≥36 patientsNervous system
9.7%Opioid Agonist9.7%Oxycodone Hcl80%Morphine Sulfate Er20%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
7 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
Johns Hopkins University
FY2026$495,606R01CA243184 - Project 1: Combined Suppression of MYC as therapy for CRPC: the COSMYC trial
Johns Hopkins University
FY2026$381,804P50CA272391
Congress activity
Updated 23 Oct 2026
80 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 2587: Development of a methylated gene panel for detection of cell-free, metastatic prostate cancer DNA in plasma
AACR Annual Meeting
AACR2026Co-author - Abstract B042: Enhancing ferroptosis in supraphysiologic androgen–treated prostate cancer through GPX4 inhibition
AACR (meeting unresolved)
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Immunometabolic effects of oral testosterone for castration-resistant prostate cancer in the ACROBAT trial.
Molecular cancer research
Article2026 - Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.
Cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerArticle2,690 citations2014
- 02Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerArticle1,158 citations2020
- 03
- 04A history of prostate cancer treatmentReview591 citations2002
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/samuel-denmeade-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
The Prostate
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Co-founder and Chief Medical Advisor
GenSpera, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)